三生製藥(1530.HK)大漲超7%有望獲突破
格隆匯7月3日丨三生製藥(1530.HK)今日大漲,現漲7.69%報10.92港元,有望突破6月17日高位創今年2月以來新高,暫成交3.7億港元,最新總市值277億港元。格隆匯平台昨日發佈深度分析文章《三生製藥(1530.HK):創新研發開花結果,商業化加速,估值有望提升》指出,目前公司PE仍處於歷史相對低位,相較於同期醫藥板塊溢價較高而言,安全墊相對較厚,成長空間較大,值得在後疫情時代之下持續關注與期待。詳情可點擊下列鏈接瞭解。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.